COMP <GO>
XERS vs SRPT // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Xeris Biopharma Holdings Inc. (NASDAQ) VS. Sarepta Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: XERS 8
— SRPT 1
■ METRIC PARITY
LAST: $10.17 (-5.04%) • MKT CAP: $1.95B
options-implied-move
—
LAST: $18.32 (-1.61%) • MKT CAP: $1.97B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XERS VS. SRPT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XERS | SRPT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.00% | -35.00% | +51.00 | XERS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 83.1x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.46% | -15.14% | +16.60 | XERS | /fcf-yield <GO> |
| Operating Margin | 8.50% | -37.50% | +46.00 | XERS | /operating-margins <GO> |
| Net Profit Margin | 0.20% | -38.30% | +38.50 | XERS | /net-margins <GO> |
| Revenue Growth (YoY) | 43.70% | 4.30% | +39.40 | XERS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.11 | 0.20 | +1.91 | XERS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 4/9 | +3.00 | XERS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.7 | 50.7 | +9.00 | XERS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.95B | $1.97B | -$14.1M | SRPT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XERS REV | SRPT REV | XERS GROSS % | SRPT GROSS % | XERS FCF | SRPT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $291.8M | $1.86B | — | 98.0% | $28.6M | -$307.5M |
| FY 2024 | $203.1M | $1.79B | — | — | -$37.0M | -$342.7M |
| FY 2023 | $163.9M | $1.14B | — | — | -$47.0M | -$501.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XERS // BETA —
SRPT // BETA —